Publications by authors named "C Cassani"
Background: Compared to male patients, sexual health remains poorly studied in women and sexual gender minority (SGM) patients with cancers.
Material And Methods: An online survey was developed by a multidisciplinary team to assess the awareness and attitude of Italian oncological providers facing sexual health during or after cancer treatment. On behalf of the respective scientific committees, the questionnaire was sent to Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies group (MITO) and to Italian Association of Radiation Oncology (AIRO) Group.
Introduction: Multilocus Inherited Neoplasia Allele Syndrome (MINAS) is a condition defined by the presence of germline pathogenic variants in more than one Cancer Susceptibility Gene (CSG). MINAS is still underreported in the literature and public databases. Since MINAS-related phenotypes are difficult to predict, case descriptions may contribute to risk assessment, treatment, and personalized surveillance for proband and relatives.
View Article and Find Full Text PDFPharmacokinetic evaluation of fezolinetant for the treatment of vasomotor symptoms caused by menopause.
Expert Opin Drug Metab Toxicol
October 2024
Article Synopsis
- Vasomotor symptoms (VMS) affect many menopausal women and can negatively impact their quality of life, with available treatments like menopausal hormone therapy (MHT) posing risks for some.
- Fezolinetant is a newly approved oral non-hormonal drug that targets neurokinin 3 receptors to help alleviate moderate to severe VMS and has demonstrated effectiveness in clinical trials.
- The drug appears to improve VMS-related issues such as sleep and overall quality of life while maintaining a safe profile, highlighting its potential as a key option for women unable to use hormone therapy, although further research is needed.
Objective: Several topical and oral drugs are available for maintenance therapy of recurrent vulvovaginal candidiasis (RVVC)(≥ 3 episodes of symptomatic Candida infection per year). The study aimed to assess the risk of early (24 weeks) and late (48-52 weeks) clinical and mycological recurrences associated with oral/topical pharmacological maintenance therapy of RVVC.
Methods: Search strategy: PubMed, EMBASE, Cochrane Library, OVID and clinical trials registers,from inception until January 2024.
Article Synopsis
- There is growing recognition that endometriosis can affect postmenopausal women, but there is still limited information available on its prevalence and clinical management in this demographic.
- Symptoms of endometriosis in menopausal patients can be vague and may appear at any stage, making accurate diagnosis challenging.
- Surgical excision remains the main treatment for symptomatic postmenopausal endometriosis, though there's ongoing debate about the use of hormone therapy due to potential risks, highlighting the need for more research in this area.